Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

Title: Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

What You Need to Know:

Compared to placebo, minocycline significantly decreased the risk of conversion from a clinically isolated syndrome (or the first demyelinating event) to multiple sclerosis (MS) over 6, but not over 24, months.

Trial Design:

Multicenter, randomized, placebo-controlled trial evaluating the effect of minocycline on the risk of conversion from a first demyelinating event to MS

142 patients with their first demyelinating symptoms occurring within the past 180 days were randomized to receive 100mg oral minocycline twice daily (n=72) or placebo (n=70) until either MS was diagnosed or 24 months after randomization